158 related articles for article (PubMed ID: 6091293)
21. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle.
Torphy TJ; Cieslinski LB
Mol Pharmacol; 1990 Feb; 37(2):206-14. PubMed ID: 2154670
[TBL] [Abstract][Full Text] [Related]
22. Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains.
Meanwell NA; Pearce BC; Roth HR; Smith EC; Wedding DL; Wright JJ; Buchanan JO; Baryla UM; Gamberdella M; Gillespie E
J Med Chem; 1992 Jul; 35(14):2672-87. PubMed ID: 1321910
[TBL] [Abstract][Full Text] [Related]
23. The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages.
Turner NC; Wood LJ; Burns FM; Gueremy T; Souness JE
Br J Pharmacol; 1993 Apr; 108(4):876-83. PubMed ID: 8387385
[TBL] [Abstract][Full Text] [Related]
24. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation.
Dickinson NT; Jang EK; Haslam RJ
Biochem J; 1997 Apr; 323 ( Pt 2)(Pt 2):371-7. PubMed ID: 9163326
[TBL] [Abstract][Full Text] [Related]
25. Effects of zaprinast and rolipram on platelet aggregation and arrhythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits.
Holbrook M; Coker SJ
Br J Pharmacol; 1991 Aug; 103(4):1973-9. PubMed ID: 1655149
[TBL] [Abstract][Full Text] [Related]
26. Antiplatelet effects of KW-7, a new inhibitor of cyclic nucleotide phosphodiesterases.
Wu CC; Wang WY; Kuo RY; Chang FR; Wu YC
Eur J Pharmacol; 2004 Jan; 483(2-3):187-94. PubMed ID: 14729106
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of human platelet cyclic AMP phosphodiesterase and of platelet aggregation by a hemisynthetic flavonoid, amentoflavone hexaacetate.
Beretz A; Briançon-Scheid F; Stierlé A; Corre G; Anton R; Cazenave JP
Biochem Pharmacol; 1986 Jan; 35(2):257-62. PubMed ID: 3002388
[TBL] [Abstract][Full Text] [Related]
28. Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility.
Meanwell NA; Dennis RD; Roth HR; Rosenfeld MJ; Smith EC; Wright JJ; Buchanan JO; Brassard CL; Gamberdella M; Gillespie E
J Med Chem; 1992 Jul; 35(14):2688-96. PubMed ID: 1321911
[TBL] [Abstract][Full Text] [Related]
29. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
Manns JM; Brenna KJ; Colman RW; Sheth SB
Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792
[TBL] [Abstract][Full Text] [Related]
30. Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent.
Masuoka H; Ito M; Sugioka M; Kozeki H; Konishi T; Tanaka T; Nakano T
Biochem Biophys Res Commun; 1993 Jan; 190(2):412-7. PubMed ID: 8381275
[TBL] [Abstract][Full Text] [Related]
31. Properties of base-substituted and carboxyl-esterified analogues of griseolic acid, a potent cAMP phosphodiesterase inhibitor.
Yasumoto T; Iijima Y; Kaneko M; Yamazaki M
Biochem Pharmacol; 1992 May; 43(10):2073-81. PubMed ID: 1318049
[TBL] [Abstract][Full Text] [Related]
32. Role of plasma adenosine in the antiplatelet action of HL 725, a potent inhibitor of cAMP phosphodiesterase: species differences.
Agarwal KC; Buckley RS; Parks RE
Thromb Res; 1987 Jul; 47(2):191-200. PubMed ID: 2821650
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of platelet aggregation by the cAMP-phosphodiesterase inhibitor, cilostamide, may not be associated with activation of cAMP-dependent protein kinase.
Nishikawa M; Komada F; Morita K; Deguchi K; Shirakawa S
Cell Signal; 1992 Jul; 4(4):453-63. PubMed ID: 1329900
[TBL] [Abstract][Full Text] [Related]
34. Involvement of cyclic GMP in the mode of action of a new antithrombotic agent PCA-4230; inhibition of the platelet cyclic GMP dependent phosphodiesterase.
Catalán RE; Martínez AM; Aragonés MD; Lombardía M
Thromb Res; 1997 Sep; 87(6):547-57. PubMed ID: 9330437
[TBL] [Abstract][Full Text] [Related]
35. [Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
Nemoz G; Prigent AF
Ann Pharm Fr; 1984; 42(2):99-112. PubMed ID: 6091520
[No Abstract] [Full Text] [Related]
36. Influence of papaverine derivatives on phosphodiesterase activity, cyclic 3',5'-AMP levels and relaxing effect on rabbit ileum.
Berndt SF; Schulz HU; Stock K
Naunyn Schmiedebergs Arch Pharmacol; 1976 Sep; 294(3):271-5. PubMed ID: 187961
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.
Verde I; Vandecasteele G; Lezoualc'h F; Fischmeister R
Br J Pharmacol; 1999 May; 127(1):65-74. PubMed ID: 10369457
[TBL] [Abstract][Full Text] [Related]
38. cGMP stimulates renin secretion in vivo by inhibiting phosphodiesterase-3.
Beierwaltes WH
Am J Physiol Renal Physiol; 2006 Jun; 290(6):F1376-81. PubMed ID: 16449359
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of a phosphodiesterase III in the lysis-sensitive target-induced elevation of cyclic AMP (cAMP) in human natural killer cells.
Whalen MM; Crews JD
Biochem Pharmacol; 2000 Aug; 60(4):499-506. PubMed ID: 10874124
[TBL] [Abstract][Full Text] [Related]
40. Cyclic nucleotide phosphodiesterase inhibition by a benzoic acid derivative.
Killackey JJ; Killackey BA; Philp RB
Agents Actions; 1985 Dec; 17(2):192-6. PubMed ID: 2420162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
